EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Theranostic Approaches to Radioiodine-Refractory Differentiated Thyroid Cancer: A Narrative Review

Petra Petranović Ovčariček iD, Murat Tuncel iD, Martin W Huellner iD, Alfredo Campennì iD, Luca Giovanella

Cancers · 14.06.2026 · 18 (12) · 1937

DOI: 10.3390/cancers18121937 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 14.06.2026. Verfasst von Petra Petranović Ovčariček und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, 10 000 Zagreb, Croatia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Radioiodine (Na[131I]I) therapy is the cornerstone of systemic treatment for differentiated thyroid cancer (DTC), exploiting sodium–iodide symporter (NIS) expression for durable control. Up to 30–40% of advanced cases develop radioiodine-refractory disease (RAI-R DTC), marked by impaired iodine uptake, aggressive behavior, and poor response to Na[131I]I. Locoregional treatments, multikinase inhibitors (MKIs), and selective targeted agents improve progression-free survival but are not curative and carry cumulative toxicity, motivating precision-based alternatives. The primary objective of this review is to clarify the evolving theranostic paradigm in RAI-R DTC; the secondary objectives are to appraise redifferentiation and iodine-based theranostics for restoring or exploiting iodine avidity and to evaluate non-iodine theranostic strategies for cases where iodine biology is absent, impaired, or unreliable.

Methods

This narrative review synthesizes contemporary evidence on theranostic strategies in RAI-R DTC, drawn from available studies, clinical trials, and current guidelines, with an emphasis on redifferentiation and non-iodine approaches; a systematic search protocol was not applied.

Results

Theranostics couples target-specific molecular imaging with matched radionuclide therapy and response-adapted sequencing. Its most transformative application is redifferentiation, in which pharmacologic modulation of oncogenic signaling can restore iodine avidity and enable renewed, dosimetry-guided Na[131I]I treatment. Beyond iodine, somatostatin receptor (SSTR) imaging and peptide receptor radionuclide therapy (PRRT) have re-emerged in very selected cases, whereas alpha emitters remain investigational. Refractoriness is increasingly viewed as a reversible continuum rather than a fixed state.

Conclusions

Theranostics can individualize RAI-R DTC treatment, restoring or exploiting iodine biology where possible and shifting to non-iodine targets where it is unreliable. Patient selection, timing, and integration with systemic therapy are central, and prospective validation is needed.

Schlagwörter

Stichwörter der Autor:innen

nuclear medicineradioiodine-refractory thyroid cancerredifferentiationtargeted therapytheranostics

Autor:innen und Institutionen

  • Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, 10 000 Zagreb, Croatia.
  • School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia.
  • Department of Nuclear Medicine, Hacettepe University, 06230 Ankara, Turkey.
  • Department of Nuclear Medicine, University Hospital of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland.
  • Department of Nuclear Medicine, University of Zurich, Pestalozzistrasse 3, 8032 Zurich, Switzerland.
  • Unit of Nuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98100 Messina, Italy.

ORCID-Profile: Petra Petranović Ovčariček, Murat Tuncel, Martin W Huellner, Alfredo Campennì

Zitieren

APA

Petranović Ovčariček, P., Tuncel, M., Huellner, M. W., Campennì, A., & Giovanella, L. (2026). Theranostic Approaches to Radioiodine-Refractory Differentiated Thyroid Cancer: A Narrative Review. Cancers, 18(12), 1937. https://doi.org/10.3390/cancers18121937

Vancouver

Petranović Ovčariček P, Tuncel M, Huellner MW, Campennì A, Giovanella L. Theranostic Approaches to Radioiodine-Refractory Differentiated Thyroid Cancer: A Narrative Review. Cancers. 2026;18(12):1937. doi:10.3390/cancers18121937

BibTeX
@article{PetranoviOvariek2026,
  author = {Petranović Ovčariček, Petra and Tuncel, Murat and Huellner, Martin W and Campennì, Alfredo and Giovanella, Luca},
  title = {Theranostic Approaches to Radioiodine-Refractory Differentiated Thyroid Cancer: A Narrative Review},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {12},
  pages = {1937},
  doi = {10.3390/cancers18121937}
}
Kostenlos starten →